These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Naltrexone and fluoxetine in Prader-Willi syndrome. Benjamin E; Buot-Smith T J Am Acad Child Adolesc Psychiatry; 1993 Jul; 32(4):870-3. PubMed ID: 8340312 [TBL] [Abstract][Full Text] [Related]
4. Hypothermia induced by risperidone and olanzapine in a patient with Prader-Willi syndrome. Phan TG; Yu RY; Hersch MI Med J Aust; 1998 Aug; 169(4):230-1. PubMed ID: 9734590 [No Abstract] [Full Text] [Related]
5. Effectiveness of naltrexone for treating pathologic skin picking behavior in an adolescent with Prader-Willi syndrome. Banga A; Connor DF J Child Adolesc Psychopharmacol; 2012 Oct; 22(5):396-8. PubMed ID: 23083028 [No Abstract] [Full Text] [Related]
6. Efficacy of risperidone treatment in Smith-Magenis syndrome (del 17 pll. 2). Niederhofer H Psychiatr Danub; 2007 Sep; 19(3):189-92. PubMed ID: 17914318 [TBL] [Abstract][Full Text] [Related]
7. Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months. Research Units on Pediatric Psychopharmacology Autism Network Am J Psychiatry; 2005 Jul; 162(7):1361-9. PubMed ID: 15994720 [TBL] [Abstract][Full Text] [Related]
9. A case series of eight aggressive young children treated with risperidone. Cesena M; Gonzalez-Heydrich J; Szigethy E; Kohlenberg TM; DeMaso DR J Child Adolesc Psychopharmacol; 2002; 12(4):337-45. PubMed ID: 12625994 [TBL] [Abstract][Full Text] [Related]
10. Catatonia in an adolescent with Prader-Willi Syndrome. Dhossche DM; Bouman NH Ann Clin Psychiatry; 1997 Dec; 9(4):247-53. PubMed ID: 9511949 [TBL] [Abstract][Full Text] [Related]
12. Clinical comparison of 59 Prader-Willi patients with and without the 15(q12) deletion. Wenger SL; Hanchett JM; Steele MW; Maier BV; Golden WL Am J Med Genet; 1987 Dec; 28(4):881-7. PubMed ID: 3688026 [TBL] [Abstract][Full Text] [Related]
13. Clinical experience with risperidone. Fras I; Major LF J Am Acad Child Adolesc Psychiatry; 1995 Jul; 34(7):833. PubMed ID: 7544342 [No Abstract] [Full Text] [Related]
14. Relationship between antipsychotics and weight in patients with Prader-Willi syndrome. Elliott JP; Cherpes G; Kamal K; Chopra I; Harrison C; Riedy M; Herk B; McCrossin M; Kalarchian M Pharmacotherapy; 2015 Mar; 35(3):260-8. PubMed ID: 25809177 [TBL] [Abstract][Full Text] [Related]
15. Obsessive-compulsive symptoms in Prader-Willi and "Prader-Willi-Like" patients. State MW; Dykens EM; Rosner B; Martin A; King BH J Am Acad Child Adolesc Psychiatry; 1999 Mar; 38(3):329-34. PubMed ID: 10087695 [TBL] [Abstract][Full Text] [Related]
16. Problem behaviors associated with deletion Prader-Willi, Smith-Magenis, and cri du chat syndromes. Clarke DJ; Boer H Am J Ment Retard; 1998 Nov; 103(3):264-71. PubMed ID: 9833657 [TBL] [Abstract][Full Text] [Related]
17. Risperidone in the treatment of behavioral disturbances in children and adolescents with borderline intellectual functioning: a double-blind, placebo-controlled pilot trial. Van Bellinghen M; De Troch C J Child Adolesc Psychopharmacol; 2001; 11(1):5-13. PubMed ID: 11322745 [TBL] [Abstract][Full Text] [Related]
18. Serum concentrations, therapeutic response and side effects in children and adolescents with impulsive-aggressive symptoms during risperidone therapy. Klampfl K; Taurines R; Preuss A; Burger R; Rothenhöfer S; Wewetzer Ch; Pfuhlmann B; Fegert J; Gerlach M; Mehler-Wex C Pharmacopsychiatry; 2010 Mar; 43(2):58-65. PubMed ID: 20336598 [TBL] [Abstract][Full Text] [Related]
19. Antipsychotic drugs in children with autism. Morgan S; Taylor E BMJ; 2007 May; 334(7603):1069-70. PubMed ID: 17525405 [TBL] [Abstract][Full Text] [Related]
20. [Treatment of behavioral disorders by risperidone in children with autism]. Wei BY; Huang F; Qin XT; Liang QQ Zhongguo Dang Dai Er Ke Za Zhi; 2011 Mar; 13(3):216-8. PubMed ID: 21426640 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]